<DOC>
	<DOCNO>NCT00334139</DOCNO>
	<brief_summary>Bisphosphonates use extensively treatment prevention skeletal complication associate bone metastasis patient breast cancer prostate cancer . The purpose study assess effect zoledronic acid patient prostate cancer breast cancer bone metastasis .</brief_summary>
	<brief_title>Effect Zoledronic Acid Bone Metabolism Patients With Bone Metastasis Prostate Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Bone Marrow Diseases</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Inclusion criterion : Prostate cancer least one cancerrelated bone lesion without hormonal treatment . Breast cancer least one cancerrelated bone lesion Negative pregnancy test screen case childbearing potential Performance status ECOG 02 Normal liver kidney function Prior surgery , chemotherapy radiotherapy allow . At least 4 week must elapse since completion surgery , chemotherapy radiotherapy breast bone . Exclusion criterion : Prior treatment bisphosphonates within 6 month study start , treatment zoledronic acid . Known hypersensitivity zoledronic acid bisphosphonates . Corrected ( adjust serum albumin ) serum calcium concentration &lt; 8.0 mg/dl ( 2.00 mmol/L ) ≥12.0mg/dl ( 3.00 mmol/L ) Current/active dental problem include infection teeth jawbone dental fixture trauma current previous osteonecrosis jaw expose bone mouth slow healing dental procedure recent ( within 6 week ) plan dental jaw surgery ( extraction , implant ) Patients clinically symptomatic brain metastasis . Severe physical psychological concomitant disease expect impair compliance provision study protocol impair assessment drug patient safety Clinically significant ascites , NYHA III IV , cardiac failure , clinically relevant pathologic finding ECG History diseases influence bone metabolism Paget´s disease primary hyperparathyroidism need treatment osteoporosis ( define accord DVO , TScore ≤2.5 ) . Previous radiation therapy bone ( include therapeutic radioisotope strontium 89 ) within 1 month Additional protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>serum bone marker</keyword>
	<keyword>bone metastasis</keyword>
	<keyword>prostate cancer</keyword>
	<keyword>breast cancer</keyword>
	<keyword>quality life</keyword>
	<keyword>bisphosphonates</keyword>
</DOC>